Holen Sie sich die Stockscreener-App
52.77
0.10%
0.05
Schlusskurs vom Vortag:
$52.72
Offen:
$52.73
24-Stunden-Volumen:
5.18M
Relative Volume:
1.21
Marktkapitalisierung:
$6.09B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-96.21M
KGV:
-51.10
EPS:
-1.0326
Netto-Cashflow:
$-82.18M
1W Leistung:
-0.20%
1M Leistung:
+23.25%
6M Leistung:
+526.04%
1J Leistung:
+2,413%
1-Tages-Spanne:
$52.70
$52.82
1-Wochen-Bereich:
$52.65
$52.89
52-Wochen-Spanne:
$1.865
$53.19
Terns Pharmaceuticals Inc Stock (TERN) Company Profile
Firmenname
Terns Pharmaceuticals Inc
Sektor
Branche
Telefon
650-525-5535 EXT.101
Adresse
1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY
Compare TERN vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TERN
Terns Pharmaceuticals Inc
|
52.77 | 6.08B | 0 | -96.21M | -82.18M | -1.0326 |
VRTX
Vertex Pharmaceuticals Inc
|
433.63 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.48 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.68 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.95 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.56 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Terns Pharmaceuticals Inc Stock (TERN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-25 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2026-02-09 | Eingeleitet | Leerink Partners | Outperform |
| 2025-11-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-11-03 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-10-15 | Eingeleitet | Truist | Buy |
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-04 | Fortgesetzt | H.C. Wainwright | Neutral |
| 2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
| 2024-10-31 | Eingeleitet | Oppenheimer | Outperform |
| 2023-06-22 | Eingeleitet | Mizuho | Buy |
| 2023-06-07 | Eingeleitet | Jefferies | Buy |
| 2023-05-31 | Eingeleitet | ROTH MKM | Buy |
| 2023-05-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-02-14 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-02-07 | Eingeleitet | UBS | Buy |
| 2022-09-12 | Eingeleitet | H.C. Wainwright | Neutral |
| 2021-09-14 | Fortgesetzt | Goldman | Buy |
| 2021-03-02 | Eingeleitet | Cowen | Outperform |
| 2021-03-02 | Eingeleitet | Goldman | Buy |
| 2021-03-02 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Terns Pharmaceuticals Inc Aktie (TERN) Neueste Nachrichten
43,857 Shares in Terns Pharmaceuticals, Inc. $TERN Acquired by SG Americas Securities LLC - MarketBeat
Capricorn Fund Managers Ltd Takes $6.12 Million Position in Terns Pharmaceuticals, Inc. $TERN - MarketBeat
Merck nears deal to buy Terns Pharmaceuticals - MSN
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B - msn.com
Aug Mood: Can Terns Pharmaceuticals Inc be the next market leaderGap Up & Real-Time Stock Entry Alerts - baoquankhu1.vn
Barclays downgrades Terns Pharmaceuticals (TERN) - MSN
Terns Pharmaceuticals Grants Inducement Shares to New Employees - National Today
Emil Kuriakose Sells 942 Shares of Terns Pharmaceuticals (NASDAQ:TERN) Stock - MarketBeat
Terns Pharmaceuticals (TERN) CMO sells shares to cover RSU taxes - Stock Titan
Press Release: Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) - Moomoo
Merck's $6.7 billion Terns Pharmaceuticals acquisition may face rival interest: Analyst - MSN
Terns Pharmaceuticals reports inducement grants to new employees under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Terns Pharmaceuticals Reports Inducement Grants To New Employees Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Three new Terns employees get 23,316 stock units over 4 years - Stock Titan
Merck nears $6 billion deal to buy Terns Pharma: Report - MSN
Merck Just Made a Big Bet on a New Cancer Growth Engine - Investing.com
Assessing Terns Pharmaceuticals (TERN) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
Terns Pharmaceuticals, Inc. $TERN Shares Purchased by JPMorgan Chase & Co. - MarketBeat
TERN Stock Chart | TERNS PHARMACEUTICALS INC (NASDAQ:TERN) - ChartMill
Merck & Co. (MRK) to acquire Terns Pharma for $6.7 billion - msn.com
This Terns Pharmaceuticals analyst is no longer bullish; here are top 4 downgrades for Monday - MSN
Merck to buy Terns for $6.7 billion to grow in blood cancers - msn.com
Truist Securities downgrades Terns Pharmaceuticals (TERN) - msn.com
Investors question premium in Merck's $6.7B deal for Terns Pharmaanalyst - msn.com
Terns Pharma (TERN) Downgraded by Truist Securities with Lowered Price Target | TERN Stock News - gurufocus.com
Terns Pharmaceuticals (NASDAQ:TERN) Earns "Hold" Rating from Truist Financial - MarketBeat
Terns Pharmaceuticals (NASDAQ:TERN) Issues Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
Barclays Downgrades Terns Pharmaceuticals(TERN.US) to Hold Rating, Cuts Target Price to $53 - Moomoo
Terns Pharmaceuticals | 10-K: Annual report - Moomoo
SLS vs. TERN: Which pharma stock has more upside as Merck eyes $6B cancer bet ahead of Keytruda patent cliff - MSN
Merck to acquire Terns in $6.7 billion deal – signaling fresh push in competitive cancer drug race - MSN
Truist Financial Downgrades Terns Pharmaceuticals(TERN.US) to Hold Rating, Cuts Target Price to $53 - Moomoo
Terns Pharmaceuticals 10-K: $0 Revenue, $(1.03) EPS - TradingView
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Merck to buy Terns Pharmaceuticals (NASDAQ: TERN) for $53 per share in cash - Stock Titan
Barclays Downgrades Terns Pharma (TERN) Rating and Lowers Price Target | TERN Stock News - GuruFocus
Terns Pharmaceuticals (NASDAQ:TERN) Earns "Equal Weight" Rating from Barclays - MarketBeat
This Terns Pharmaceuticals Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday - Benzinga
Terns Pharmaceuticals faces final earnings under acquisition cloud By Investing.com - Investing.com Canada
Terns Pharmaceuticals faces final earnings under acquisition cloud - investing.com
Merck to Buy Terns Pharmaceuticals to Strengthen Drug Pipeline - Chemical Industry Digest
Barclays Downgrades Terns Pharmaceuticals to Equalweight From Overweight, Cuts Price Target to $53 From $56 - marketscreener.com
Barclays cuts Terns Pharmaceuticals stock rating on Merck deal By Investing.com - Investing.com Canada
Finanzdaten der Terns Pharmaceuticals Inc-Aktie (TERN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Terns Pharmaceuticals Inc-Aktie (TERN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Burroughs Amy L. | Chief Executive Officer |
Mar 16 '26 |
Option Exercise |
4.64 |
14,583 |
67,665 |
303,559 |
| Burroughs Amy L. | Chief Executive Officer |
Mar 16 '26 |
Sale |
46.71 |
14,583 |
681,108 |
288,976 |
| Burroughs Amy L. | Chief Executive Officer |
Feb 17 '26 |
Option Exercise |
4.64 |
14,583 |
67,665 |
303,559 |
| Burroughs Amy L. | Chief Executive Officer |
Feb 17 '26 |
Sale |
39.19 |
14,583 |
571,579 |
288,976 |
| Burroughs Amy L. | Chief Executive Officer |
Jan 15 '26 |
Option Exercise |
4.64 |
68,749 |
318,995 |
357,725 |
| Burroughs Amy L. | Chief Executive Officer |
Jan 15 '26 |
Sale |
37.07 |
68,749 |
2,548,603 |
288,976 |
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):